Cardiovascular effects of estrogen in postmenopausal women.
- Author:
Wen-ling ZHU
1
Author Information
1. Department of Cardiology, PUMC Hospital, CAMS, PUMC, Beijing 100730, China. zhuwenling@sohu.com
- Publication Type:Clinical Trial
- MeSH:
Arteriosclerosis;
prevention & control;
Coronary Disease;
prevention & control;
Double-Blind Method;
Estradiol;
therapeutic use;
Estrogen Replacement Therapy;
Female;
Humans;
Medroxyprogesterone;
therapeutic use;
Middle Aged;
Postmenopause
- From:
Acta Academiae Medicinae Sinicae
2002;24(4):409-412
- CountryChina
- Language:Chinese
-
Abstract:
Cardiovascular disease continues to be the leading cause of morbidity and mortality among the postmenopausal women. Several randomized clinical trials to determine whether hormone replacement therapy (HRT) has a cardioprotective role and several others are currently underway. The results' however were controversial. During the past 3 years, a number of randomized clinical trials have investigated the role of HRT in primary and secondary prevention of clinical and anatomical manifestations of atherosclerosis and the clinical results suggest that HRT can not decrease cardiovascular events or slow down the development of atherosclerosis in women with established coronary heart disease (CHD). In contrast, HRT has been showed to possibly effective in women without CHD as primary prevention.
